NCT06607185 2026-03-13A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT06630325 2026-01-07A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic CancerOHSU Knight Cancer InstitutePhase 2 Active not recruiting30 enrolled
NCT04956640 2025-09-25Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)Eli Lilly and CompanyPhase 1/2 Recruiting540 enrolled
NCT05059522 2025-06-25Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingPfizerPhase 3 Active not recruiting68 enrolled